Since the BARD1 isoforms are highly expressed in NSCLCs, Pilyguin et al. proposed that the detection of antibodies in patients’ sera against the tumor-associated antigens present on the BARD1 isoforms could be used to predict the presence of lung cancer [124]. Here, BARD1 is linked to lung cancer.